Carotid Artery Disease Market 2020–By Identifying The Key Market Segments And Key Players Holding Market Share

 The Global Carotid Artery Disease Market is expected to register a CAGR of 4.1% to reach USD 11,621.6 million till 2023.

Market Dynamics

Carotid artery disease is a condition in which plaques are developed in the arteries that supply blood to the brain, which often lead to strokes. The prominent factors that drive the market growth are increasing geriatric population, increasing adoption of an unhealthy lifestyle, and the popularity of over-the-counter (OTD) drugs. However, the high cost of diagnostics and surgeries and stringent government regulations for the carotid artery disease are likely to restrain market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6301

Carotid arteries are blood vessels in the neck that supply oxygen-rich blood to the brain. These vessels could get blocked by plaque, a fatty substance consisting of cholesterol, calcium, and other materials. Medication helps to reduce plaque build-up in carotid arteries and blood vessels throughout the body. Ardent efforts by manufacturers of therapeutic drugs for the treatment of carotid artery disease have aided the growth of the global carotid artery disease market. Medications often prescribed for carotid artery disease are antiplatelet medications, anticoagulant medications, tissue plasminogen activator (tPA). The most commonly used anti-platelet medication is aspirin. Other drugs include clopidogrel (Plavix) and dipyridamole (Persantine), which may be prescribed alone or in combination with aspirin to reduce the risk of stroke. This factor is expected to lead to the growth of the global carotid artery disease market and may even increase the revenue-generation ability of market players. The current first line of treatment for carotid artery disease includes anti-platelets medication and tissue plasminogen activator (tPA). The increasing demand for over-the-counter drugs by the patient population is boosting the growth of the market.

Segmentation

The global carotid artery disease market, diagnosis & treatment, has been segmented into diagnosis and treatment. Based on treatment, the market has been further divided into medications and surgical procedures. The medications segment has been sub-segmented into cholesterol-lowering statins, antiplatelet drugs, antihypertensive drugs. The surgical procedures segment has been further divided into carotid endarterectomy, carotid artery angioplasty & stenting, and carotid artery bypass.

Based on end user, the carotid artery disease market has been categorized as hospital & clinics, ambulatory surgical centers, pharmacies, and others.

Regional Analysis

The global carotid artery disease market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest share in the global carotid artery disease market owing to the rising prevalence of chronic diseases, increasing levels of certain fats and cholesterol in the blood, and stringency of government regulations for drug development. According to the 2014 Surgeon General’s Report on smoking and health, it was estimated that 4,00,000 patients aged 70 years and older in the US suffered from asymptomatic carotid artery stenosis.

The European market was the second largest in 2017 in terms of market share. Factors such as growth in the biopharmaceutical sector, increasing government funding to promote research for the prevention of chronic diseases, the presence of developed economies, high per capita disposable incomes, and increased healthcare spending by consumers are driving the growth of the market in this region. According to the World Diabetes Foundation Organization, the number of people estimated to be suffering from diabetes in 2015 was 59.8 million. The increasing cases of diabetes are likely to drive the carotid artery disease market.

In 2017, Asia-Pacific was the third-largest in the global carotid artery disease market owing to a large number of research organizations, low manufacturing and labor cost, development of new infrastructure to support the healthcare industry, and increasing investments by major players. According to the India Brand Equity Foundation, India is becoming a leader in clinical trials, and contract research and manufacturing activities as the cost of drug production in the country are ~33% lower than that of the US. All these factors are likely to contribute to the fastest growth of the Asia-Pacific region during the forecast period.

Key Players

The prominent players in the global carotid artery disease market are W. L. Gore & Associates, Inc., Becton, Dickinson and Company, Terumo Corporation, Hitachi, Ltd, Silk Road Medical, Inc., Abbott, Medtronic, Stryker Corporation, Cardinal Health, and Boston Scientific Corporation.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301

Drug of Abuse Testing Market 2020 - Opportunity, Driving Trends And Deep Study 2023

 Drug of Abuse Testing Market is likely to register a CAGR of 7.77% and is projected to reach USD 6,673.3 Million by 2025. Drug of abuse testing is based on diagnosing drug addiction, also called substance use disorder, requiring a thorough evaluation and often includes an assessment by a psychiatrist, a psychologist, or a licensed alcohol and drug counselor. Blood, urine, or other lab tests are used to assess drug use, but they’re not a diagnostic test for addiction. These tests may be used for monitoring treatment.

Several factors such as increased use of drug testing at an organizational level, growing production and trade of illicit drugs worldwide, rise in road accidents and death rates, and the rise in the consumption of illegal drugs are driving the growth of the market. However, the inability of testing products to detect low-dose designer drugs, social issues associated with drug abuse testing, and legalization of drugs are a threat to the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1930

Market Dynamics

Drug testing in the workplace has traditionally been conducted using collection and analysis of urine. Urine as a specimen for drug testing allows for a long window of detection. Drug of abuse testing has been increasingly used by the American and European organizations at various levels like pre-employment screening, random drug/alcohol screening, post-incident drug or alcohol screening, and abstinence monitoring. Testing has become mandatory for multiple national and international organizations such as the International Olympic Committee (IOC), International Sports Federation (ISF) and National Olympic Committee, to stop drug abuse in sports. Thus, the market is projected to grow at a steady rate during the forecast period.

Segmentation

Based on the type of test, the global drug of abuse testing market has been segmented into onsite screening test and laboratory drug testing. The onsite screening test segment held a market share of 71.62% in 2018. Based on the sample, the global drug of abuse testing market has been segmented into by urine, saliva, hair, and others.

Key Players

The Major Players in the Global Drug Of Abuse Testing Market are Quest Diagnostics (US), Laboratory Corporation of America Holdings (LabCorp) (US), Abbott Laboratories (US), Randox laboratories (UK), Bio-Rad Laboratories, Inc. (the US), Sonic Healthcare (Australia), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific, Inc. (US).

Some of the key strategies followed by the players operating in the global drug of abuse testing market were mergers, acquisitions, and new product launches.

Regional Analysis

The Global Drug of Abuse Testing Market, on the basis of region, is divided into North America, Europe, Asia-Pacific, and the rest of the world. The North American region is projected to dominate the global drug of abuse testing market. The growth is mainly attributable to the increasing use of illicit drugs in the region. In order to reduce the cases of drug abuse, the US government has been taking various initiatives like mandatory drug testing in multiple departments including defense, oil, and gas, mining and department of transportation (DOT). Drug testing has also been made a mandatory process in educational institutions.

The European market for drug of abuse testing is projected to be the second-largest during the forecast period. The broad market size of the region is a result of government initiatives to curb abuse and increasing alcohol-related accidents in the region, which leads to a greater emphasis on the use of testing equipment.

Asia-Pacific is the fastest-growing market for drug of abuse testing. This owes to the rise in alcohol consumption and strict government rules and regulations about testing drug consumption in the region.

The rest of the world is expected to grow at a steady rate due to the increasing awareness created by public and private organizations.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/drug-abuse-testing-market-1930

MRSA Drugs Market 2020 Share, Trend, Segmentation And Forecast To 2023

 The Global MRSA Drugs Market is expected to register a CAGR of 4.4% to reach USD 4,312.2 million till 2023. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2102

The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.

Market Dynamics

MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period.

Segmentation

The global MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others.

Regional Analysis

The global MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016.

Europe holds the second position in global MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA.

Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the global MRSA drugs market.

Key Players

The prominent players in the global MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102

Global Genitourinary Drugs Market By Major Industry Trends And Forecast Business Opportunities And Threats In The Next 5 Years

 Global viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the global viral vector manufacturing market is expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6890

Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.

However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.

Segmentation:

The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.

The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.

The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.

The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.

The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.

The market, by application, has been segmented into gene therapy and vaccinology.

The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890

Genitourinary Drugs Market 2020 Market Challenge, Driver, Trends & Forecast To 2023

 The global genitourinary drugs market is accounted for USD 28,200 million expected  and expected to register CAGR ~1.65% during the forecast period (2018–2023).

Genitourinary disorders are caused by damage to urinal or genital part of the human body. Kidney, bladder, ureter and urethra are parts of genitourinary system, genitourinary drugs are used to treat the  medical complications caused to these parts. The rising prevalence of genitourinary disorders, increasing number of pipeline drugs, and technological advancement in genitourinary diagnosis are expected to drive the growth of the market. According to the U.S. National Library of Medicine more than 480 clinical trials are lined up for treatment of urinary tract infection.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6802

Health Information Center, Moreover, rising R&D spending and collaborative strategies adopted by the top players such as licensing and agreements are contributing to the growth of the market. For instance, in October 2018, Novartis AG signed a licensing agreement with Boston Pharmaceuticals for manufacturing and marketing of its three anti-infective products LYS228, IID572, and MAK181.

The increasing emergence of counterfeit drugs, rising generics drug competition, and high number of patent expirations may hamper the growth of the market during the assessment period.

Segmentation

The global genitourinary drugs market has been segmented on the basis of disease, product, and end-user.

On the basis of disease, the market has been classified urinary tract infections, erectile dysfunction, urinary incontinence & overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, prostate cancer, and others.

The product segment has been divided into urologicals, hormonal therapy, gynecologicals, and anti-infectives.

The market, by end-user, has been segmented into hospitals, clinics, super specialty centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The genitourinary drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European genitourinary drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The genitourinary drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The genitourinary drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are likely to dominate the global genitourinary drugs market owing to the rising prevalence of genitourinary disorders in aging population, increase in the healthcare expenditure,  and  the presence of a well-established healthcare system. According to the National Kidney Foundation, Urinary tract infections (UTIs) are responsible for nearly 10 million doctor visits each year and approximately 20% women suffer from UTI at least once in a life.

The European market is expected to be the second-largest genitourinary drugs market. The market growth in this region can be attributed to the increasing research and development, rise in number of chronic diseases such as diabetes, and government initiatives for the development of healthcare sector. According to the International Diabetes Foundation, diabetes is major health concern in European region and in 2017, approximately 9.1% of total European population was suffering from diabetes.

Asia-Pacific is expected to be the fastest-growing genitourinary drugs market during the forecast period owing to the increasing geriatric production along with rise in number of genitourinary disorders, rising investments in healthcare and expansions by market players in the region. According to United Nations, Department of Economic and Social Affairs, in 2016, 12.4% of total population in Asian countries was 60 year or older.

The market in the Middle East & Africa is expected to hold the smallest share of the global genitourinary drugs market due to lack of technical knowledge, undeveloped healthcare sector, and poor medical facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/genitourinary-drugs-market-6802

Cell Harvesting Market 2020 Market Challenge, Driver, Trends & Forecast To 2023

 The global cell harvesting market is expected to grow significantly over the forecast period. It is estimated that the global cell harvesting market is expected to register a CAGR of Approx. 8.75% with an estimated market value of USD 209.5 million during the forecast period from  2018 to 2023. Cell harvesting is performed by separating the cell culture from the growing medium, involving techniques such as centrifugation, microfiltration, and depth filtration.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6801

Numerous factors such as an increase in chronic infections and diseases, the rapid growth of the biotechnology and pharmaceutical industries, and rising research in regenerative medicines are expected to drive the growth of the market. Moreover, the cost-effectiveness, ease of use, the durability of harvesters, technological advancements, and design development of cell harvester devices fuel the growth of the market. Several companies are also involved in new product launches to strengthen their position in the market. For instance, in September 2018, AVITA Medical, a global regenerative medicine company, announced that the US Food and Drug Administration (FDA) approved the Company’s Premarket Approval (PMA) application to market the RECELL Autologous Cell Harvesting Device (RECELL System). This device helps to treat severe burns in patients of 18 years and older.

Key players:

ads-tec GmbH, Argos Technologies, Inc., Arthrex, Inc., Avita Medical, Bertin, connectorate, Cox Scientific, hynoDent AG, PerkinElmer Inc., Scinomix, Teleflex Incorporated, and TERUMO CORPORATION are some of the key players in the global cell harvesting market.

Intended Audience

• Pharmaceutical companies
• Biotechnology companies
• Cell harvester vendors
• Research and Development (R&D) companies
• Government research institutes
• Academic institutes and universities

However, the technical complexity of harvesters, coupled with ethical issues related to embryonic stem cell research may curb the growth of the market. Stringent government regulations and mandatory licensing rules may also hamper the market growth during the assessment period.

Market Segmentation:

The global cell harvesting market has been segmented into product type, application, and end user.

The market, on the basis of product type, has been segmented into manual cell harvesters and automated cell harvesters.

The manual cell harvesters segment is estimated to hold the largest share owing to the high preferability of manual cell harvesters, whereas the automated cell harvesters segment is expected to be the fastest growing segment due to increased awareness and rise in the use of automated technologies in devices.

The market, by application, has been segmented into biopharmaceutical application, stem cell research, and others.

The market, by end user, has been segmented into pharmaceutical companies, biotechnology companies, research institutes, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global cell harvesting market owing to a well-developed healthcare sector and growing healthcare expenditure. For instance, according to the data published by the Committee for a Responsible Federal Budget in May 2018, the US spent about USD 3.5 trillion, or 18% of its Gross Domestic Product (GDP) on health expenditures, which accounted for more than twice the average among developed countries in  2017. Additionally, many companies in this region focus on the innovation of new treatment options, thus being a lucrative option for the growth of the market in this region.

Europe is expected to hold the second largest position in the global cell harvesting market. The market growth in this region owes to the availability of funds for research. For instance, according to the data published by the National Institute of Health Funding (NIHR) in 2016, funding of EUR 928 million was announced for new NIHR Biomedical Research Centers (BRC) and NIHR Clinical Research Facilities (CRF) for five years starting from April 2017.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-harvesting-market-6801

Bioburden Testing Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2023

 The global neuroprosthetics market was estimated USD 5.28 billion in 2016 and expected to reach USD 10.48 billion by 2023 at a CAGR of 12.4% from 2018 to 2023.

Neuroprosthetics are medical devices that are developed in such a way that provide signal to the central nervous system and receive indications from the external environment. These devices are used in neural diseases such as Epilepsy, Parkinson’s disease, Visual Prosthetics and many more.

The factors responsible for the positive growth of this market are increasing prevalence of neural diseases, over active bladder syndrome, and chronic disorder which include epilepsy.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6782

 However, factors such as, low acceptance of neuroprosthetics treatment devices due to its high cost, and low awareness about the devices may restrict the market growth during the forecast period.

Segmentation:

The global neuroprosthetics market is segmented on the basis of type, technology, applications, and end users. On the basis of type the market is segmented into output neural prosthetics and input neural prosthetics. The output is segmented into cognitive prosthetics, and motor prosthetics. The input is segmented into cochlear implant, and visual prosthetic.

 On the basis of techniques, the market is segmented into vagus nerve stimulation, deep brain stimulation, sacral nerve stimulation, and spinal cord stimulation.

On the basis of application, the market is segmented into motor neuron disorders, physiological disorders, and cognitive disorders. The motor neuron disorders are segmented into Parkinson’s disease, and Epilepsy disorder. The physiological disorders are segmented into auditory processing disorders, ophthalmic disorders, cardiovascular disorders, and urology disorders. Furthermore, the cognitive disorders include disorders such as Alzheimer’s disease, paralysis, and severe depression. On the basis of end-users, the market is segmented into hospitals and clinics, diagnostic centers, research centers and others.

On the basis of region, the global Neuroprosthetics market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players:

Some of the key players in the global neuroprosthetics market are Medtronic (US), Abbott (US), Cochlear (Australia), Boston Scientific (US), Livanova (UK), Second Sight (US), Med-El (UK), Retina Implant (US), Sonova (UK), Neuropace (US), Nevro (California), and others. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/neuroprosthetics-market-6782